incretin mimetic agents glp 1 receptor agonists GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1-based therapies for type 2

Hepatobiliopancreatic AEs are also discussed in brief because, although they are extremely infrequent, it is important to exercise caution with those patients with a history of pancreatic and gallbladder disorders

Semaglutide carries a warning about thyroid tumors found in animal studies

Keywords: pediatric obesity, GLP-1 receptor agonists, semaglutide, adolescent weight management, pharmacotherapy, long-term safety, health equity, obesity treatment Introduction The global pediatric obesity epidemic represents one of the most pressing public health challenges of the 21st century

The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action

doi: 10.1111/dom.14280